Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
US Department of Veterans Affairs
With
Immunex Corporation
SmithKline Beecham
Amgen
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients in the following disease categories will be considered eligible for this study:
Any acute leukemia beyond an initial attempt to induce a remission or after relapse
Chronic Myelogenous Leukemia in Blast Phase
Refractory Multiple Myeloma
Refractory non-Hodgkin's and Hodgkin's Lymphoma
Patients must be more than 14 days beyond prior myelotoxic chemotherapy
Several other eligibility criteria apply.
You may not be if
None
Clareo Health | Use of Topotecan in Patients With Refractory Acute Leukemia
